Firefly Neuroscience, Inc. (AIFF)
| Market Cap | 21.60M |
| Revenue (ttm) | 74,000 |
| Net Income (ttm) | -7.75M |
| Shares Out | 8.50M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,784 |
| Open | 2.800 |
| Previous Close | 2.800 |
| Day's Range | 2.460 - 3.030 |
| 52-Week Range | 2.460 - 15.900 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About AIFF
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly ... [Read more]
News
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's du...
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that impro...
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly's advanced AI BNA technology analysis platform During the Ph...
Firefly Neuroscience to Participate in Upcoming October Investor Conferences
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
Partnership will expand Firefly's FDA Cleared BNA™ technology to more hospitals and physician offices Partnership will expand Firefly's FDA Cleared BNA™ technology to more hospitals and physician offi...
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright's 26th Annual Global Investment Conference September 9-11
TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neu...
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
NCD Will Integrate Firefly's BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes NCD Will Integrate Firefly's BNA Technology into it...
UPDATE -- Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq
TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neu...